for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zealand Pharma Aktieselskabet

ZEAL.OQ

Latest Trade

31.33USD

Change

-1.47(-4.48%)

Volume

3,731

Today's Range

31.33

 - 

34.30

52 Week Range

11.30

 - 

34.97

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
32.80
Open
34.08
Volume
3,731
3M AVG Volume
3.74
Today's High
34.30
Today's Low
31.33
52 Week High
34.97
52 Week Low
11.30
Shares Out (MIL)
35.80
Market Cap (MIL)
8,256.23
Forward P/E
-18.72
Dividend (Yield %)
--

Latest Developments

More

Zealand Pharma Q3 Operating Result Turns To Loss Of DKK 130.1 Million

Zealand Pharma Acquires Encycle Therapeutics

Zealand Pharma Achieves Primary And All Key Secondary Endpoints In Pediatric Phase 3 Trial With Dasiglucagon

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zealand Pharma Aktieselskabet

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

Industry

Biotechnology & Drugs

Contact Info

Smedeland 36

+45.null.88773600

https://www.zealandpharma.com/

Executive Leadership

Alf Gunnar Martin Nicklasson

Independent Chairman of the Board

Emmanuel Dulac

Chief Executive Officer

Kirsten Aarup Drejer

Independent Vice Chairman of the Board

Matthew Dallas

Chief Financial Officer, Senior Vice President

Adam Steensberg

Executive Vice President, Chief Medical and Development Officer (CMDO)

Key Stats

1.89 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2016

0.2K

2017

0.1K

2018

0.0K

2019(E)

0.2K
EPS (DKK)

2016

-6.330

2017

-9.770

2018

18.940

2019(E)

-12.296
Price To Earnings (TTM)
--
Price To Sales (TTM)
192.19
Price To Book (MRQ)
5.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.86
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-38.36
Return on Equity (TTM)
-31.41

Latest News

Latest News

BRIEF-Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln

* REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018

BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome

* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME

BRIEF-Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon

Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu :

BRIEF-Zealand Pharma Enters Collaboration Agreement With Roche Diabetes Care

* HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE

BRIEF-Zealand Pharma: Positive Results From First Phase 3 Trial For Treatment Of Severe Hypoglycemia

* REG-ZEALAND PHARMA'S FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA SUCCESSFULLY MEETS ITS PRIMARY OBJECTIVE

BRIEF-Zealand Pharma FY Net Loss At DKK 272.3 Million​

* FY 2017 REVENUE DKK 139.8 MILLION VERSUS DKK 234.8 MILLION YEAR AGO

BRIEF-Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates

* REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017

* REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017

BRIEF-Zealand: Clinical Evidence Support Potential For Glepaglutide

* ZEALAND HAS COMPLETED A PHARMACOKINETIC (PK) STUDY WITH GLEPAGLUTIDE THAT CONFIRMS POTENTIAL FOR ONCE-WEEKLY DOSING

BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism

* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018

BRIEF-Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics

* ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC.

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.

BRIEF-Zealand reports royalty revenue Of DKK 10.3 mln for Q3

* REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017

BRIEF-Zealand Pharma granted orphan drug designation by FDA

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

New Zealand forestry a first test in nationalist party's protectionist agenda

Some New Zealand forest owners are suspending replanting of trees and re-thinking investments as the country's third-largest export earner finds itself in the sights of maverick politician Winston Peters' protectionist agenda.

BRIEF-Zealand Pharma to cooperate with Torrey Pines Institute for Molecular Studies

* REG-ZEALAND PHARMA AND TORREY PINES INSTITUTE FOR MOLECULAR STUDIES ANNOUNCE RESEARCH COLLABORATION

BRIEF-Zealand Pharma and Orbit Discovery enter into research collaboration

* REG-ZEALAND AND ORBIT DISCOVERY ENTER INTO RESEARCH COLLABORATION

BRIEF-Zealand Pharma to present at Morgan Stanley Global Healthcare Conference

* REG-ZEALAND PHARMA TO PRESENT AT MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE IN NEW YORK ON SEPTEMBER 12, 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Zealand Pharma Q2 operating loss widens to DKK 94.8 mln

* H1 REVENUE OF DKK 88.4 MILLION/USD 13.6 MILLION (DKK 14.7 MILLION/USD 2.2 MILLION IN FIRST HALF OF 2016)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up